ScholarIQanswers from OpenAlex & ORCID
David Waterhouse
ResearcherPublications, citations & collaboration network
David Waterhouse is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does David Waterhouse have?
ScholarIQindexed works
David Waterhouse has 295 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does David Waterhouse have?
ScholarIQcitation count
David Waterhouse has 22,172 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of David Waterhouse?
ScholarIQh-index
David Waterhouse has an h-index of 48 in OpenAlex.
What is the i10-index of David Waterhouse?
ScholarIQi10-index
David Waterhouse has an i10-index of 114 in OpenAlex.
What is the ORCID of David Waterhouse?
ScholarIQorcid
The ORCID for David Waterhouse is on the source record.
What is the OpenAlex record for David Waterhouse?
ScholarIQopenalex
The OpenAlex for David Waterhouse is on the source record.
What are the most-cited papers on David Waterhouse?
ScholarIQmost cited works
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Paul Baas, Lucio Crinò, Wilfried Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Płużański, Everett E. Vokes, Esther Holgado, David Waterhouse, Neal Ready, Justin F. Gainor, Osvaldo Arén Frontera, Libor Havel, Martin Steins, Marina Chiara Garassino, Joachim G.J.V. Aerts, Manuel Dómine, Luis Paz‐Ares, Martin Reck, Christine Baudelet, Christopher Harbison, Brian Lestini, David R. Spigel
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
M.C. Liu, Geoffrey R. Oxnard, Eric A. Klein, Charles Swanton, Michael V. Seiden, M.V. Seiden, Minetta C. Liu, Geoffrey R. Oxnard, Eric A. Klein, David A. Smith, Donald Richards, Timothy J. Yeatman, Allen Lee Cohn, Rosanna L. Lapham, Jessica Clément, Alexander S. Parker, Mohan K. Tummala, Kristi McIntyre, Mikkael A. Sekeres, Alan H. Bryce, Robert D. Siegel, Xuezhong Wang, David Cosgrove, Nadeem R. Abu‐Rustum, Jonathan C. Trent, David D. Thiel, Carlos Becerra, Manish Agrawal, Lawrence Garbo, Jeffrey K. Giguere, Ross M. Michels, Ronald P. Harris, Stephen Richey, Timothy A. McCarthy, David Waterhouse, Fergus J. Couch, Sharon Wilks, Amy Krie, Rama Balaraman, Álvaro Restrepo, Michael W. Meshad, Kimberly Rieger‐Christ, Travis Sullivan, Christine Lee, Daniel Greenwald, William Oh, Che‐Kai Tsao, Neil Fleshner, Hagen F. Kennecke, Maged Khalil, David R. Spigel, Atisha Manhas, Brian Ulrich, P. Kovoor, Christopher Stokoe, Jay Courtright, Habte Yimer, Timothy Larson, Charles Swanton, Michael V. Seiden, Michael V. Seiden, Steven R. Cummings, Farnaz Absalan, Gregory E. Alexander, Brian C. Allen, Hamed Amini, Alexander M. Aravanis, Siddhartha Bagaria, Leila Bazargan, John F. Beausang, Jennifer R. Berman, Craig Betts, Alexander W. Blocker, Joerg Bredno, Robert Calef, Gordon Cann, Jeremy G. Carter, Christopher Chang, Hemanshi Chawla, Xiaoji Chen, Tom C. Chien, Daniel Civello, Konstantin Davydov, Vasiliki Demas, Mohini Desai, Zhao Dong, Saniya Fayzullina, Alexander P. Fields, Darya Filippova, Peter Freese, Eric T. Fung, Sante Gnerre, Samuel Gross, Meredith Halks‐Miller, Megan P. Hall, Anne‐Renee Hartman, Chenlu Hou, Earl Hubbell, Nathan Hunkapiller, Karthik A. Jagadeesh
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
Leora Horn, David R. Spigel, Everett E. Vokes, Esther Holgado, Neal Ready, Martin Steins, Elena Poddubskaya, Hossein Borghaei, Enriqueta Felip, Luis Paz‐Ares, Adam Płużański, Karen L. Reckamp, Marco Angelo Burgio, Martin Kohlhäeufl, David Waterhouse, Fabrice Barlési, Scott Antonia, Óscar Arrieta, Jérôme Fayette, Lucio Crinò, Naiyer A. Rizvi, Martin Reck, Matthew D. Hellmann, William J. Geese, Ang Li, Anne Blackwood‐Chirchir, Diane Healey, Julie R. Brahmer, Wilfried Eberhardt
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer
Hossein Borghaei, Scott Gettinger, Everett E. Vokes, Laura Q.M. Chow, Marco Angelo Burgio, Javier de Castro, Adam Płużański, Óscar Arrieta, Osvaldo Arén Frontera, Rita Chiari, Charles Butts, Joanna Wójcik-Tomaszewska, Bruno Coudert, Marina Chiara Garassino, Neal Ready, Enriqueta Felip, M. Alonso Garcìa, David Waterhouse, Manuel Dómine, Fabrice Barlési, Scott Antonia, M Wohlleber, David E. Gerber, Grzegorz Czyżewicz, David R. Spigel, Lucio Crinò, Wilfried Eberhardt, Ang Li, S. Marimuthu, Julie R. Brahmer
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim, Julien Mazières, Johan Vansteenkiste, H. Léna, Jesus Corral Jaime, Jhanelle E Gray, John D. Powderly, C. Chouaïd, Paolo Bidoli, Paul Wheatley‐Price, Keunchil Park, Ross A. Soo, Yifan Huang, Catherine Wadsworth, Phillip A. Dennis, Naiyer A. Rizvi, Luis Paz-Ares Rodríguez, Silvia Novello, Sandrine Hiret, Peter Schmid, Eckart Laack, Raffaele Califano, Makoto Maemondo, Sang‐We Kim, Jamie E. Chaft, David Vicente Baz, Thierry Berghmans, Dong‐Wan Kim, Veerle Surmont, Martin Reck, Ji‐Youn Han, Esther Holgado Martin, Cristóbal Belda-Iniesta, Yuichiro Oe, Antonio Chella, Akhil Chopra, G. Robinet, Héctor Soto Parrà, Michael J. Thomas, Parneet Cheema, Nobuyuki Katakami, Wu‐Chou Su, Young‐Chul Kim, Juergen Wolf, Jong-Seok Lee, Hideo Saka, Michele Stanislaw Milella, Inmaculada Ramos García, Anne Sibille, Takashi Yokoi, Eun Joo Kang, Shinji Atagi, E. Spaeth-Schwalbe, Makoto Nishio, Fumio Imamura, Nashat Gabrail, Rémi Veillon, Sofie Derijcke, Tadashi Maeda, Dylan M. Zylla, Kendra Kubiak, Armando Santoro, Ma. Noemi Uy, Sarayut Lucien Geater, Antoîne Italiano, Dariusz M. Kowalski, Fabrice Barlési, Yuh‐Min Chen, David R. Spigel, Busyamas Chewaskulyong, Ramón García Gómez, Rosa Álvarez, Chih-Hsin Yang, Te‐Chun Hsia, Fabrice Denis, Hiroshi Sakai, Mark Vincent, Kōichi Goto, Joaquim Bosch‐Barrera, Glen J. Weiss, Jean-Luc Canon, Christian W. Scholz, Massimo Aglietta, Hirotsugu Kemmotsu, Koichi Azuma, Penelope A. Bradbury, Ronald Feld, Abraham Chachoua, Jacek Jassem, Rosalyn A. Juergens, Ramon Palmero Sanchez, Albert Malcolm, Nandagopal Vrindavanam, Kaoru Kubota, Cornelius F. Waller, David Waterhouse, Bruno Coudert, Z. Mark